Physician profile
Bijoy Abraham
NPI 1164860482
$1,529.72
in general payments reported to CMS, 2019-2025
15 companies · $192 in 2025
The $192 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2020: $14.28 · 2021: $90.38 · 2022: $363 · 2023: $687 · 2024: $47.53 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $733.16 | 2019-2025 | Grafix Pl, Stravix, Oasis |
| Organogenesis INC. | $303.64 | 2022-2024 | Puraply |
| Stryker Corporation | $181.06 | 2021-2024 | Actishield Cf, Infinity, Infinity Adaptis |
| Zimmer Biomet Holdings, INC. | $59.47 | 2021 | |
| Amgen INC. | $49.11 | 2025 | Krystexxa |
| Treace Medical Concepts, INC. | $45.18 | 2023 | |
| Orthofix Medical, INC. | $26.84 | 2023 | Physio-Stim |
| Fusion Orthopedics USA, LLC | $22.35 | 2025 | |
| Paragon 28, INC. | $19.46 | 2023 | Activcore Nail |
| Grt US Holding, INC. | $17.30 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.37 | 2023 | Seglentis |
| Averitas Pharma INC. | $15.16 | 2023 | Qutenza |
| Ibsa Pharma INC. | $14.61 | 2023 | Tirosint, Licart |
| Tactile Systems Technology INC | $13.76 | 2022 | |
| Next Science LLC | $13.25 | 2023 | Blastx, Xperience, Surgx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bijoy Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.